Healthcare

Oncology testing volumes accelerated to 32% growth in the quarter, underpinned by expanding adoption of the company's diagnostic platform. The Minimal Residual Disease segment — which involves detecting traces of cancer remaining after treatment — saw particularly rapid expansion, with approximately 12,000 tests performed …

The INFORM-MS trial evaluated intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in patients with non-active secondary progressive MS (na-SPMS) — a disease state characterized by the gradual accumulation of neurological disability independent of acute relapses. The dual primary endpoints required the trial to …

George Lederman, Ph.D., joins Tonix as Executive Vice President of Strategy and Transformation, a newly defined role that combines responsibilities more typically held by separateBusinessfunctions — operational AI deployment and business development deal-making. His prior experience includes an associate partner role at McKinsey and …

The Phase 1 study is designed as an open-label, dose-escalation trial with the primary objectives of evaluating the safety, tolerability, and pharmacokinetics of intravesically administered UGN-501. The trial will also aim to determine a recommended Phase 2 dose. Eligible participants include adults with recurrent …

Invex released its September quarter report and Appendix 4C on 30 October 2026. Subsequent to quarter end, as announced on 26 October, the company entered a binding share purchase agreement to acquire 100% of Rekover Therapeutics, a New Zealand biotechnology company.

Argenica released its quarterly update and Appendix 4C on 30 October 2026. The company said it had completed a Phase 2 clinical trial of xaranetide in acute ischaemic stroke patients at Australian hospitals during 2025, and it is now designing a targeted late-stage trial …

BCAL released its quarterly activities report and Appendix 4C on 30 October 2026. The company completed clinical validation of BREASTESTplus 2 for women aged 30 and over across all breast densities. In the validation study the test showed a sensitivity of 80.3% and a …